670 related articles for article (PubMed ID: 17383140)
41. [In vitro activity of trovafloxacin, of other fluoroquinolones and of related antimicrobials against clinical isolates. Grupo colaborativo WHONET-Argentina].
Rossi A; Galas M; Tokumoto M; Guelfand L; Lopardo H
Medicina (B Aires); 1999; 59 Suppl 1():8-16. PubMed ID: 10436549
[TBL] [Abstract][Full Text] [Related]
42. Antimicrobial activity of doripenem tested against prevalent Gram-positive pathogens: results from a global surveillance study (2003-2007).
Fritsche TR; Sader HS; Stillwell MG; Jones RN
Diagn Microbiol Infect Dis; 2009 Apr; 63(4):440-6. PubMed ID: 19302928
[TBL] [Abstract][Full Text] [Related]
43. In vitro activities of 11 fluoroquinolones against 226 Campylobacter jejuni strains isolated from Finnish patients, with special reference to ciprofloxacin resistance.
Lehtopolku M; Hakanen AJ; Siitonen A; Huovinen P; Kotilainen P
J Antimicrob Chemother; 2005 Dec; 56(6):1134-8. PubMed ID: 16223936
[TBL] [Abstract][Full Text] [Related]
44. Nonfermentative gram-negative bacilli in cancer patients: increasing frequency of infection and antimicrobial susceptibility of clinical isolates to fluoroquinolones.
Rolston KV; Kontoyiannis DP; Yadegarynia D; Raad II
Diagn Microbiol Infect Dis; 2005 Mar; 51(3):215-8. PubMed ID: 15766609
[TBL] [Abstract][Full Text] [Related]
45. Comparison of disk diffusion, VITEK 2, and broth microdilution antimicrobial susceptibility test results for unusual species of Enterobacteriaceae.
Stone ND; O'Hara CM; Williams PP; McGowan JE; Tenover FC
J Clin Microbiol; 2007 Feb; 45(2):340-6. PubMed ID: 17135429
[TBL] [Abstract][Full Text] [Related]
46. Effect of 1-(1-naphthylmethyl)-piperazine, a novel putative efflux pump inhibitor, on antimicrobial drug susceptibility in clinical isolates of Enterobacteriaceae other than Escherichia coli.
Schumacher A; Steinke P; Bohnert JA; Akova M; Jonas D; Kern WV
J Antimicrob Chemother; 2006 Feb; 57(2):344-8. PubMed ID: 16354746
[TBL] [Abstract][Full Text] [Related]
47. Comparative antimicrobial activity of lomefloxacin, norfloxacin, ofloxacin, ciprofloxacin and enoxacin against > 500 bacterial isolates.
Ismaeel NA; Tayeb OS
Microbios; 1993; 74(300):147-54. PubMed ID: 8396196
[TBL] [Abstract][Full Text] [Related]
48. Doripenem activity tested against a global collection of Enterobacteriaceae, including isolates resistant to other extended-spectrum agents.
Mendes RE; Rhomberg PR; Bell JM; Turnidge JD; Sader HS
Diagn Microbiol Infect Dis; 2009 Apr; 63(4):415-25. PubMed ID: 19249175
[TBL] [Abstract][Full Text] [Related]
49. Comparative in vitro antimicrobial activity of a novel quinolone, garenoxacin, against aerobic and anaerobic microbial isolates recovered from general, vascular, cardiothoracic and otolaryngologic surgical patients.
Edmiston CE; Krepel CJ; Kehl KS; Seabrook GR; Somberg LB; Almassi GH; Smith TL; Loehrl TA; Brown KR; Lewis BD; Towne JB
J Antimicrob Chemother; 2005 Nov; 56(5):872-8. PubMed ID: 16186167
[TBL] [Abstract][Full Text] [Related]
50. Reevaluation of Enterobacteriaceae MIC/disk diffusion zone diameter regression scattergrams for 9 beta-lactams: adjustments of breakpoints for strains producing extended spectrum beta-lactamases.
Jones RN; Craig WA; Ambrose PG; Dudley MN; Pottumarthy S
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):235-46. PubMed ID: 16105568
[TBL] [Abstract][Full Text] [Related]
51. A multicenter study on the comparative in vitro activity of fleroxacin and three other quinolones: an interim report from 27 centers.
Beskid G; Prosser BL
Am J Med; 1993 Mar; 94(3A):2S-8S. PubMed ID: 8383919
[TBL] [Abstract][Full Text] [Related]
52. Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin.
Falagas ME; Maraki S; Karageorgopoulos DE; Kastoris AC; Mavromanolakis E; Samonis G
Int J Antimicrob Agents; 2010 Mar; 35(3):240-3. PubMed ID: 20034765
[TBL] [Abstract][Full Text] [Related]
53. In vitro activity of fosfomycin against ciprofloxacin-resistant or extended-spectrum beta-lactamase-producing Escherichia coli isolated from urine and blood.
Ko KS; Suh JY; Peck KR; Lee MY; Oh WS; Kwon KT; Jung DS; Lee NY; Song JH
Diagn Microbiol Infect Dis; 2007 May; 58(1):111-5. PubMed ID: 17300900
[TBL] [Abstract][Full Text] [Related]
54. Antimicrobial susceptibility profiles among common respiratory tract pathogens: a GLOBAL perspective.
Sahm DF; Brown NP; Thornsberry C; Jones ME
Postgrad Med; 2008 Sep; 120(3 Suppl 1):16-24. PubMed ID: 18931467
[TBL] [Abstract][Full Text] [Related]
55. Ocular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolates.
Asbell PA; Colby KA; Deng S; McDonnell P; Meisler DM; Raizman MB; Sheppard JD; Sahm DF
Am J Ophthalmol; 2008 Jun; 145(6):951-958. PubMed ID: 18374299
[TBL] [Abstract][Full Text] [Related]
56. [Surveillance of antimicrobial resistance among nosocomial gram-negative pathogens from 15 teaching hospitals in China in 2005].
Yang QW; Xu YC; Chen MJ; Hu YJ; Ni YX; Sun JY; Yu YS; Kong HS; He L; Wu WY; Ye HF; Yang YM; Zhu LN; Guo SH; Ji P; Zhu ZH; Ren JK; Zhang LX; Sun ZY; Zhu XH; Tong MQ; Zhao WS; Mei YN; Liu Y; Zhang ZJ; Duan Q; Li D; Liu PP; Wang J; Han LX; Wang H; Xie XL
Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(39):2753-8. PubMed ID: 18167265
[TBL] [Abstract][Full Text] [Related]
57. Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward Gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA).
Rhomberg PR; Fritsche TR; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2006 Sep; 56(1):57-62. PubMed ID: 16631338
[TBL] [Abstract][Full Text] [Related]
58. Validity of nalidixic acid screening in fluoroquinolone-resistant typhoid salmonellae.
Butt T; Khan MY; Ahmad RN; Salman M; Afzal RK
J Coll Physicians Surg Pak; 2006 Jan; 16(1):31-4. PubMed ID: 16441985
[TBL] [Abstract][Full Text] [Related]
59. Regional variations in multidrug resistance among Enterobacteriaceae in the USA and comparative activity of tigecycline, a new glycylcycline antimicrobial.
DiPersio JR; Dowzicky MJ
Int J Antimicrob Agents; 2007 May; 29(5):518-27. PubMed ID: 17376657
[TBL] [Abstract][Full Text] [Related]
60. In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART).
Paterson DL; Rossi F; Baquero F; Hsueh PR; Woods GL; Satishchandran V; Snyder TA; Harvey CM; Teppler H; Dinubile MJ; Chow JW
J Antimicrob Chemother; 2005 Jun; 55(6):965-73. PubMed ID: 15849262
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
